A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

NCT04688931 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

282

Enrollment

INDUSTRY

Sponsor class

Stopped Alternate approach pursued

Conditions

Bladder Cancer
Urothelial Carcinoma
Urothelial Carcinoma Bladder

Interventions

DRUG: UGN-102
PROCEDURE: TURBT

Sponsor

UroGen Pharma Ltd.